Uses its proprietary TransCon technology to create best-in-class therapies for unmet medical needs in endocrinology and oncology.
Ascendis Pharma A/S is a dynamic biopharmaceutical company dedicated to addressing unmet medical needs through innovative therapies. Established in 2006 and headquartered in Hellerup, Denmark, Ascendis Pharma focuses on pioneering treatments that offer transformative solutions to patients worldwide.
At the forefront of Ascendis Pharma's portfolio is SKYTROFA, a groundbreaking therapy designed for individuals suffering from growth hormone deficiency (GHD). The company also leads in the development of TransCon Growth Hormone, catering to pediatric and adult GHD, as well as Turner syndrome. Additionally, Ascendis Pharma advances TransCon Parathyroid Hormone for adults with hypoparathyroidism and TransCon C-type natriuretic peptide targeting achondroplasia.
Further enhancing its pipeline, Ascendis Pharma is actively developing TransCon toll-like receptors 7/8 agonist for intratumoral delivery and TransCon IL-2 ß/? for systemic delivery, demonstrating its commitment to expanding therapeutic options across various medical domains. With a steadfast commitment to innovation and patient-centric solutions, Ascendis Pharma continues to shape the future of biopharmaceuticals through cutting-edge research and development initiatives.